18 MONTH A1C AND WEIGHT OUTCOMES OF EXENATIDE THERAPY IN PATIENTS WITH TYPE-2 DIABETES IN A REAL-WORLD STUDY

被引：2
|
作者：
Brixner, D. [1 ]
McAdam-Marx, C. [1 ]
Ye, X. [1 ]
Misurski, D. [2 ]
Wintle, M. [3 ]
Fabunmi, R. [3 ]
机构：
[1] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73550-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A97 / A97
页数：1
相关论文
共 50 条
  • [41] Digital nutritional therapy in patients with type 2 diabetes: a real-world outcome analysis
    Sutter, A.
    Jones, L.
    Ghosh, A.
    Schenk, M.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S377 - S377
  • [42] Real-world outcomes with different technology modalities in type 1 diabetes
    Beato-Vibora, Pilar, I
    Gallego-Gamero, Fabiola
    Ambrojo-Lopez, Ana
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (06) : 1845 - 1850
  • [43] The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy
    Thayer, Sarah
    Wei, Wenhui
    Buysman, Erin
    Brekke, Lee
    Crown, William
    Grabner, Michael
    Raparla, Swetha
    Quimbo, Ralph
    Cziraky, Mark J.
    Hu, Wenli
    Cuddihy, Robert
    ADVANCES IN THERAPY, 2013, 30 (12) : 1128 - 1140
  • [44] The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy
    Sarah Thayer
    Wenhui Wei
    Erin Buysman
    Lee Brekke
    William Crown
    Michael Grabner
    Swetha Raparla
    Ralph Quimbo
    Mark J. Cziraky
    Wenli Hu
    Robert Cuddihy
    Advances in Therapy, 2013, 30 : 1128 - 1140
  • [45] RELATIONSHIP BETWEEN HEMOGLOBIN A1c AND ISCHEMIC STROKE AMONG PATIENTS WITH TYPE-2 DIABETES
    Chaveepojnkamjorn, Wisit
    Boonrasri, Wandee
    Viwatwongkasem, Chukiat
    Siri, Sukhontha
    Kriengkaisakda, Warakorn
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2019, 50 (05) : 935 - 941
  • [46] Real-World Treatment Responses from Electronic Medical Record (EMR) Data among Patients with Type 2 Diabetes (T2D) Receiving Basal Insulin either with Mealtime Insulin or Exenatide BID, by A1c Attainment Level and Baseline A1c
    Lang, Kathleen
    Hiep Nguyen
    Huang, Huan
    Kaufman, Elise
    Levin, Philip
    DIABETES, 2016, 65 : A402 - A402
  • [47] The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Twelve-Month Data Analysis
    Guerci, Bruno
    Giorgino, Francesco
    Garcia, Luis-Emilio
    Boye, Kristina
    Norrbacka, Kirsi
    Sapin, Helene
    Heitmann, Elke
    Lebrec, Jeremie
    Dib, Anne
    Federici, Marco O. Orsini
    DIABETES, 2021, 70
  • [48] THE REAL-WORLD OBSERVATIONAL PROSPECTIVE STUDY OF HEALTH OUTCOMES WITH DULAGLUTIDE & LIRAGLUTIDE IN TYPE 2 DIABETES PATIENTS (TROPHIES): 6-MONTH ANALYSIS RESULTS
    Giorgino, F.
    Guerci, B.
    Garcia-Perez, L. E.
    Boye, K.
    Aigner, U.
    Heitmann, E.
    Federici, Orsini M.
    Zimner-Rapuch, S.
    Rosilio, M.
    Norrbacka, K.
    Sapin, H.
    VALUE IN HEALTH, 2020, 23 : S506 - S506
  • [49] Real- world characteristics and A1C outcomes in younger (<70 years) and older (≥70 years) patients with type 2 diabetes mellitus: the Diabetes FORWARD study.
    Videlefsky, Andrea
    Stewart, John
    Vlajnic, Aleksandra
    Dex, Terry
    Dalal, Mehul
    PHARMACOTHERAPY, 2014, 34 (10): : E199 - E199
  • [50] Real-world comparative outcomes study in US patients with type 2 diabetes initiating basal insulin analogues
    Davis, K. L.
    Meyers, J. L.
    Tangirala, M.
    Wei, W.
    DIABETOLOGIA, 2012, 55 : S384 - S384
12345